We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TERIFLUNOMIDE-AX, TERIFLUNOMIDE APOTEX (Apotex Pty Ltd)
Product name
TERIFLUNOMIDE-AX, TERIFLUNOMIDE APOTEX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
242 working days (255)
Active ingredients
teriflunomide
Registration type
New generic medicine
Indication
TERIFLUNOMIDE-AX, TERIFLUNOMIDE APOTEX are indicated for the treatment of patients with relapsing forms of Multiple Sclerosis to reduce the frequency of clinical relapses and to delay the progression of physical disability.